Screening for cervical cancer can be cost-effective;Screening för cervixcancer kan vara kostnadseffektiv: Kombinationen cellprov och HPV-test skulle ge ytterligare vinster

Lakartidningen

Volumn 102, Issue 24-25, 2005, Pages 1874-1879

  Bistoletti, Peter ^a   Ellström, Agneta ^b   Dillner, Joakim ^c   Sennfält, Karin ^a   Sparén, Pär ^d   Strander, Björn ^e  

^a LINKÖPING UNIVERSITY   (Sweden)

^b Mödrahälsovårdsöverläkare   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e Kungsbacka Sjukhus Och Onkologiskt Centrum   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; CYTOLOGY; DNA DETERMINATION; HEALTH CARE POLICY; HUMAN; UTERINE CERVIX CARCINOMA;

ADULT; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; MODELS, ECONOMIC; PAPILLOMAVIRIDAE; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 21344456166     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Gustafsson L, Adami HO. Optimization of cervical cancer screening. Cancer Causes and Control 1992;3:125-36.
2. Böhmer G, van den Bruule A, Brummer O, Meijer C, Petry U. No comfirmed case of HPV DNA-negative CIN3 or invasive primary cancer of the uterine cervix among 511 patients. Am J Obstet Gynecol 2003;189:118-20.
3. Monsonego J, Xavier-Bosch F, Coursaget P. Cervical cancer control, priorities and new directions. Int J Cancer 2004;108:329-33.
4. Wright T, Schiffman M, Solomon D. Interim guidance for the use of HPV DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004;103:304-9.
5. Briggs A, Sculpher M. An introduktion to Markov modelling for economic evaluation. PharmacoEconomics 1998;13(4):397-409.
6. van Ballegooijen M, van den Akker-van Marle ME, Warmerdam PG, Meijer CJ, Walboomers JM, Habbema JD. Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-) effectiveness. Br J Cancer 1997;76:651-7.
7. van den Akker-van Marle ME, van Ballegooijen M, van Ortmaarssen GJ, Boer R, Habbema JD. Cost-effectiveness of cervical cancer screening: comparison of screening policies. J Natl Cancer Inst 2002;94:193-204.
8. Briggs AH. Handling uncertainty in cost-effectiveness models. PharmacoEconomics 2000;17(5):479-500.
9. Forslund O, Antonsson A, Edlund K. Population-based type-specific prevalence of high-risk HPV infection in middle aged Swedish women. J Med Virol 2002;66:535-41.
10. Lörincz A, Richart R. HPV DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med 2003;127:959-68.
11. Talbäck M, Stenbeck M, Rosen M, Barlow L, Glimelius B. Cancer survival in Sweden 1960-1998. Acta Oncol 2003;42:637-59.
12. Pettersson F, Malker B. Invasive carcinoma of the uterine cervix following diagnosis and treatment of in situ carcinoma. Record linkage study within a national cancer registry. Radiother Oncol 1989;16:115-20.
13. Näslund I. Evaluation of screening procedures for uterine cervical carcinoma. Stockholm: Karolinska institutet; 1985.
14. Dillner J. Primary screening for HPV infection. Best Pract Res Clin Obstet Gynaecol 2001;15:743-57.
15. IARC working group on evaluation of cervical cancer screening programmes. Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. BMJ 1986;293:659-64.
16. van den Akker-van Marle ME, van Ballegooijen M, Rozendaal L, Meijer CJ, Habbema JD. Extended duration of the detectable stage by adding HPV test in cervical cancer screening. Br J Cancer 2003;89:1830-3.
17. Hakama M, Hristova L. Effect of screening in the Nordic cancer control group up to the year 2017. Acta Oncol 1997;36:119-28.
18. Hemminki K, Xinjun L, Mutanen P. Age-incidence relationship and time trends in cervical cancer in Sweden. Eur J Epidemiol 2001;17:323-8.
19. Stenkvist B, Bergström R, Eklund G, Fox C. Papanicolaou smear screening and cervical cancer. JAMA 1984;252:1423-6.
20. Mandelblatt J, Fahs M. The cost-effectiveness of cervical cancer screening for low-income elderly women. JAMA 1988;259:2409-13.